GlobeNewswire: Viventia Bio Inc. Contains the last 10 of 7 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T11:22:50ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2015/09/17/769153/10149719/en/Viventia-Expands-Leadership-Team-Names-Arthur-P-DeCillis-M-D-as-Chief-Medical-Officer.html?f=22&fvtc=4&fvtv=26186Viventia Expands Leadership Team, Names Arthur P. DeCillis, M.D., as Chief Medical Officer2015-09-17T18:45:00Z<![CDATA[WINNIPEG, Manitoba, Sept. 17, 2015 (GLOBE NEWSWIRE) -- Viventia Bio Inc., a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents, today announced that Arthur P. DeCillis, M.D., has been appointed to the position of Chief Medical Officer. Dr. DeCillis will lead the advancement of Viventia's product pipeline as the Company prepares to commence late stage trials of its two lead candidates, Vicinium™ and Proxinium™, which are being developed for the treatment of patients with high-grade non-muscle invasive bladder cancer (NMIBC) and late-stage squamous cell carcinoma of the head and neck (SCCHN), respectively. Viventia also is progressing an earlier-stage pipeline of de-immunized, systemic anti-cancer Targeted Protein Therapeutic (TPT) candidates. Dr. DeCillis will report to Viventia's Chief Executive Officer Stephen Hurly.]]>https://www.globenewswire.com/news-release/2015/09/04/766248/10148345/en/Viventia-Reports-on-Progress-of-Anti-Cancer-Pipeline-at-PEGS-Korea-2015.html?f=22&fvtc=4&fvtv=26186Viventia Reports on Progress of Anti-Cancer Pipeline at PEGS Korea 20152015-09-04T16:10:00Z<![CDATA[Viventia's Targeted Protein Therapeutics (TPTs) Have Been Designed to Overcome the Efficacy and Safety Challenges of Existing Antibody-Drug Conjugates WINNIPEG, Manitoba and PHILADELPHIA, Sept. 4, 2015 (GLOBE NEWSWIRE) -- Viventia Bio Inc., a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents, announced that Gregory P. Adams, Ph.D., Chief Development Officer, delivered the keynote presentation ("Targeted Protein Therapeutics (TPTs) for the Treatment of Cancer") at the PEGS Korea 2015 Protein and Antibody Engineering Summit, held this week in Seoul, Republic of Korea. Dr. Adams reviewed the Company's substantial progress in advancing its proprietary TPT programs into late-stage clinical testing, as well as earlier-stage programs.]]>https://www.globenewswire.com/news-release/2015/07/16/752692/10141297/en/Viventia-Recognizes-Chairman-Leslie-Dan-s-50-Years-of-Leadership-in-Healthcare.html?f=22&fvtc=4&fvtv=26186Viventia Recognizes Chairman Leslie Dan's 50 Years of Leadership in Healthcare2015-07-16T12:00:00Z<![CDATA[WINNIPEG, Manitoba, July 16, 2015 (GLOBE NEWSWIRE) -- Viventia Bio Inc., a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents, today recognized Leslie L. Dan, Founder and Chairman of Viventia, for his 50 years of leadership in the life sciences. In 1965, Mr. Dan founded the generic pharmaceuticals company Novopharm Ltd., which grew to become the second-largest generic drug manufacturer in Canada prior to its acquisition by pharmaceutical company Teva Pharmaceutical Industries Ltd. in 2000. A widely respected businessman, Mr. Dan is acknowledged for his dedication to corporate responsibility and philanthropy and was made a Member of the Order of Canada and awarded the Order of Ontario for his many contributions.]]>https://www.globenewswire.com/news-release/2015/07/02/749484/10140532/en/Viventia-Begins-Recruitment-of-Clinical-Centers-as-it-Prepares-to-Initiate-Phase-3-Clinical-Trial-of-Vicinium-TM-for-the-Treatment-of-Non-Muscle-Invasive-Bladder-Cancer.html?f=22&fvtc=4&fvtv=26186Viventia Begins Recruitment of Clinical Centers as it Prepares to Initiate Phase 3 Clinical Trial of Vicinium(TM) for the Treatment of Non-Muscle-Invasive Bladder Cancer2015-07-02T16:45:00Z<![CDATA[Patient Enrollment to Begin Shortly at Multiple Clinical Trial Centers in North America WINNIPEG, Manitoba, July 2, 2015 (GLOBE NEWSWIRE) -- Viventia Bio Inc., a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents, today announced that they have begun approving clinical trial centers for participation in its pivotal Phase 3 human clinical trial for Vicinium™. A recombinant fusion protein, Vicinium (also referred to as VB4-845) is being developed for treatment of high grade non-muscle invasive bladder cancer (NMIBC). Based on discussions with the U.S. Food and Drug Administration, Viventia has finalized its clinical protocol and plans to start enrolling patients within the next month at multiple sites in the US and Canada. Preliminary efficacy data from the trial are expected in the third quarter of 2016.]]>https://www.globenewswire.com/news-release/2015/06/23/746661/10138136/en/Viventia-Announces-2015-Additions-to-Its-Board-of-Directors.html?f=22&fvtc=4&fvtv=26186Viventia Announces 2015 Additions to Its Board of Directors2015-06-23T12:00:00Z<![CDATA[WINNIPEG, Manitoba, June 23, 2015 (GLOBE NEWSWIRE) -- Viventia Bio Inc., a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents, today announced the expansion of its Board of Directors resulting from the additions of four industry veterans in 2015; George Bickerstaff, Annalisa Jenkins, MBBS, MRCP, Catherine J. Mackey, Ph.D., and Sanford Zweifach, all of whom are accomplished leaders in the life sciences with extensive operational experience. The presence of these Board members is intended to complement the continued growth of Viventia's programs and pipeline as the Company prepares to advance two lead clinical candidates, Vicinium™ and Proxinium™, into Phase III testing this year for bladder cancer and head & neck cancer, respectively. The Company also has an earlier-stage pipeline of de-immunized, systemic anti-cancer Targeted Protein Therapeutic product candidates entering Phase I/II in Q1 2016. The total number of Viventia's Board members is seven, including Board Chair Leslie L. Dan, who is also Founder of Viventia, Dr. Martin Barkin of the University of Toronto and Stephen Hurly the Company CEO.]]>https://www.globenewswire.com/news-release/2015/06/17/745278/10138747/en/Viventia-Presents-Validating-Evidence-for-Highly-Differentiated-De-immunized-Payload-for-Oncology-at-13th-Empowered-Antibodies-Conference.html?f=22&fvtc=4&fvtv=26186Viventia Presents Validating Evidence for Highly Differentiated De-immunized Payload for Oncology at 13th Empowered Antibodies Conference2015-06-17T12:00:00Z<![CDATA[- Viventia's Protein Toxin DeBouganin Shows Advantages in Uniform Killing of Diverse Cancer Cell Lines, Avoidance of Multi-Drug Resistance Affecting Small Molecule Toxins, and Efficacy against Cancer Stem Cells -]]>https://www.globenewswire.com/news-release/2015/06/05/742454/10137443/en/Viventia-Bio-Inc-Expands-Leadership-Team-Names-Erick-Lucera-as-Chief-Financial-Officer-and-Gregory-Adams-Ph-D-Chief-Product-Development-Officer.html?f=22&fvtc=4&fvtv=26186Viventia Bio Inc. Expands Leadership Team, Names Erick Lucera as Chief Financial Officer and Gregory Adams, Ph.D., Chief Product Development Officer2015-06-05T12:00:00Z<![CDATA[WINNIPEG, Manitoba, June 5, 2015 (GLOBE NEWSWIRE) -- Viventia Bio Inc., a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents, today announced the expansion of the Company's leadership team with the appointments of Erick Lucera to the position of Chief Financial Officer and Gregory Adams, Ph.D., to the newly created position of Chief Product Development Officer. Mr. Lucera will be responsible for all financial planning and reporting and will head investor relations and external communications activities. Dr. Adams will lead Viventia's team in advancing the company's oncology pipeline of novel Targeted Protein Therapeutics, fully biologic engineered proteins based on human antibody fragments that effectively deliver cytotoxic payloads directly to tumor cells. Viventia is anticipated to advance two lead clinical candidates, Vicinium™ and Proxinium™, into Phase 3 testing this year for bladder cancer and head & neck cancer, respectively. The Company also has an earlier-stage pipeline of de-immunized, systemic anti-cancer product candidates entering Phase 1/2 in Q1 2016. The appointments of Dr. Adams and Mr. Lucera are effective immediately, and both individuals will report to Stephen Hurly, Viventia's Chief Executive Officer.]]>